Tag Archives: Taylor Feehley

Chardan Capital Thinks Synlogic Inc’s Stock is Going to Recover

Chardan Capital analyst Taylor Feehley reiterated a Buy rating on Synlogic Inc (SYBX – Research Report) today and set a price target of $20. The company’s shares closed yesterday at $6.27, close to its 52-week low of $5.75. Feehley said:

Chardan Capital Keeps a Buy Rating on Synlogic Inc (SYBX)

Chardan Capital analyst Taylor Feehley reiterated a Buy rating on Synlogic Inc (SYBX – Research Report) today and set a price target of $20. The company’s shares closed yesterday at $8.26. Feehley noted: “We are highly encouraged by progress in

Evelo Biosciences Inc (EVLO) Receives a Hold from Chardan Capital

Chardan Capital analyst Taylor Feehley reiterated a Hold rating on Evelo Biosciences Inc (EVLO – Research Report) today and set a price target of $10. The company’s shares opened today at $8.40. Feehley said: “We have previously expressed some concern

Chardan Capital Sticks to Its Buy Rating for Seres Therapeutics (MCRB)

In a report released today, Taylor Feehley from Chardan Capital reiterated a Buy rating on Seres Therapeutics (MCRB – Research Report), with a price target of $15. The company’s shares closed yesterday at $6.11. According to TipRanks.com, Feehley is a

Chardan Capital Reaffirms Their Hold Rating on Assembly Biosciences (ASMB)

In a report released today, Taylor Feehley from Chardan Capital reiterated a Hold rating on Assembly Biosciences (ASMB – Research Report), with a price target of $30. The company’s shares closed on Friday at $18.79, close to its 52-week low

Chardan Capital Keeps Their Buy Rating on Synlogic Inc (SYBX)

Chardan Capital analyst Taylor Feehley reiterated a Buy rating on Synlogic Inc (SYBX – Research Report) today and set a price target of $20. The company’s shares opened today at $8.47. Feehley wrote: “We continue to be encouraged by the